Today: 20 May 2026
Browse Category

NYSE:DBI 9 December 2025

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

Aimei Health Technology shares surged 968% to $85.47 Tuesday after the SPAC extended its merger deadline to January 6, 2026, fueling speculation of a pending deal. The S&P 500 closed down 0.02%, while microcap stocks dominated gains, with Oriental Culture Holding up 321% and Netcapital up 122%. Trading in AFJK exceeded 6 million shares, far above its average.
9 December 2025
··········

Stock Market Today

  • Williams-Sonoma Gains 1.58% as Market Declines, Eyes Upcoming Earnings
    May 19, 2026, 7:31 PM EDT. Williams-Sonoma (WSM) shares rose 1.58% to $171.83, outperforming the S&P 500's 0.67% drop. The stock had declined 16.27% over the past month, lagging the sector's 0.69% loss but behind the S&P 500's 4% gain. Investors await WSM's upcoming earnings report, expected to show $1.80 per share in EPS, down 2.7% year-over-year, with revenue projected to rise 4.25% to $1.8 billion. The company's full-year estimates anticipate 4.75% EPS growth and 4.39% revenue growth. Analyst estimate revisions have nudged EPS projections higher by 0.58% in 30 days, with WSM holding a Zacks Rank #3 (Hold). Valuation indicators show a Forward P/E of 18.27, slightly below industry average, while the PEG ratio of 2.12 exceeds the Retail - Home Furnishings sector average of 1.63.

Latest articles

James Hardie Drops After Warning on Housing, Even With Q4 Beat

James Hardie Drops After Warning on Housing, Even With Q4 Beat

20 May 2026
James Hardie’s U.S.-listed shares dropped 6.1% Tuesday and slid another 2.6% after hours after reporting a 35% fall in quarterly net income to $28.5 million, despite a 45% jump in net sales to $1.40 billion. The company cited weak housing demand and warned the market remains uncertain. ASX shares had not traded post-earnings; they last closed at A$26.78, up 2.9%.
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

20 May 2026
SELLAS Life Sciences shares rose 4.1% to $7.59 Tuesday after CEO Angelos Stergiou said its Phase 3 AML trial is two events from final analysis. The company reported $107.1 million in cash and a first-quarter net loss of $8.4 million. The REGAL trial’s main measure is overall survival. SELLAS remains blinded to results until the 80th event triggers data review.
Red Robin Shares Rise After Earnings Beat

Red Robin Shares Rise After Earnings Beat

20 May 2026
Red Robin shares surged 15.6% after hours to $4.45 Tuesday, following first-quarter revenue of $378.3 million that beat Wall Street estimates despite a 0.6% drop in comparable sales and a 1.6% decline in guest traffic. Net loss was $2.2 million, or 12 cents per share. The company reaffirmed its 2026 outlook and said refranchising talks are in final stages.
Go toTop